References
1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the
BNT162b2 mRNA Covid-19 Vaccine. NEJM. 2020; 383:2603-2615.
2. Voysey M, Costa Clemens SA, Madhi SA, et al. Safety and efficacy of
the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim
analysis of four randomized controlled trials in Brazil, South Africa,
and the UK. The Lancet. 2021; 397:99-111.
3. Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are
highly expressed in nasal epithelial cells together with innate immune
genes. Nat Med. 2020; 26: 681-687.
4. Chan RWY, Liu S, Cheung JY, et al. Study on the mucosal and
serological immune reponse to the novel coronavirus (SARS-CoV-2)
vaccines. MedRxiv preprint doi:
https://doi.org/10.1101/2021.06.15.21256661
5. Berings M, Arasi S, De Ruyck N, et al. Reliable mite-specific IgE
testing in nasal secretions by means of allergen microarray. JACI. 2017;
140:301-303.